Acorda Therapeutics Inc (ACOR): Insiders Are Dumping, Should You?

Page 1 of 2

Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds’ portfolio at the end of the fourth quarter of 2012. ACOR investors should pay attention to a decrease in support from the world’s most elite money managers of late. There were 15 hedge funds in our database with ACOR positions at the end of the previous quarter.

In the financial world, there are plenty of metrics investors can use to track Mr. Market. A duo of the best are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best fund managers can outclass the market by a significant amount (see just how much).

Equally as integral, positive insider trading activity is another way to parse down the world of equities. There are plenty of incentives for a bullish insider to get rid of shares of his or her company, but only one, very clear reason why they would initiate a purchase. Various empirical studies have demonstrated the market-beating potential of this tactic if investors know where to look (learn more here).

With all of this in mind, let’s take a peek at the latest action regarding Acorda Therapeutics Inc (NASDAQ:ACOR).

Hedge fund activity in Acorda Therapeutics Inc (NASDAQ:ACOR)

In preparation for this year, a total of 10 of the hedge funds we track held long positions in this stock, a change of -33% from the third quarter. With the smart money’s capital changing hands, there exists a few key hedge fund managers who were boosting their holdings meaningfully.

Of the funds we track, SAC Capital Advisors, managed by Steven Cohen, holds the most valuable position in Acorda SAC CAPITAL ADVISORSTherapeutics Inc (NASDAQ:ACOR). SAC Capital Advisors has a $18.7 million position in the stock, comprising 0.1% of its 13F portfolio. Coming in second is Millennium Management, managed by Israel Englander, which held a $10.2 million position; 0.1% of its 13F portfolio is allocated to the stock. Some other hedge funds with similar optimism include Samuel Isaly’s OrbiMed Advisors, Jim Simons’s Renaissance Technologies and Sean Cullinan’s Point State Capital.

Since Acorda Therapeutics Inc (NASDAQ:ACOR) has faced declining sentiment from the smart money, we can see that there exists a select few hedgies that decided to sell off their entire stakes last quarter. At the top of the heap, Roberto Mignone’s Bridger Management sold off the largest investment of the “upper crust” of funds we monitor, totaling about $19.2 million in stock., and Mark Broach of Manatuck Hill Partners was right behind this move, as the fund dumped about $3.8 million worth. These bearish behaviors are interesting, as aggregate hedge fund interest was cut by 5 funds last quarter.

What do corporate executives and insiders think about Acorda Therapeutics Inc (NASDAQ:ACOR)?

Insider trading activity, especially when it’s bullish, is best served when the company we’re looking at has seen transactions within the past half-year. Over the last six-month time period, Acorda Therapeutics Inc (NASDAQ:ACOR) has experienced zero unique insiders buying, and 7 insider sales (see the details of insider trades here).

Let’s also examine hedge fund and insider activity in other stocks similar to Acorda Therapeutics Inc (NASDAQ:ACOR). These stocks are Synageva BioPharma Corp (NASDAQ:GEVA), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Sarepta Therapeutics Inc (NASDAQ:SRPT), ImmunoGen, Inc. (NASDAQ:IMGN), and Nektar Therapeutics (NASDAQ:NKTR). This group of stocks are the members of the biotechnology industry and their market caps match ACOR’s market cap.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

The 50 Best Personal Finance Blogs

Most Expensive Apartments in New York City

Bloodiest UFC Fights Ever Fought

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!